{"schema_version":"secwatch.filing_event.v1","accession":"0001384101-21-000138","form_type":"8-K","ticker":"VCYT","cik":"0001384101","company_name":"VERACYTE, INC.","filed_at":"2021-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.905820+00:00","generated_at":"2026-06-30T00:54:13.041721+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Veracyte Q2 revenue $55.1M (+166% YoY); raises 2021 guidance to $200-208M","bullets":["Total revenue $55.1M, up 166% YoY; net loss $9.0M ($0.13 per share) improved 18%.","Genomic test volume 20,856, up 215% YoY and 44% sequentially.","Raises FY2021 revenue guidance to $200-208M from $190-200M.","Received Medicare coverage for Decipher Bladder; signed managed care contract for Decipher Prostate (~20M members).","Planned HalioDx acquisition announced; new CFO, CBO, CIO appointed."],"urls":{"canonical":"https://secwatch.observer/filing/0001384101-21-000138","json":"https://secwatch.observer/filing/0001384101-21-000138.json","markdown":"https://secwatch.observer/filing/0001384101-21-000138.md","text":"https://secwatch.observer/filing/0001384101-21-000138.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1384101/000138410121000138/0001384101-21-000138-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1384101/000138410121000138/vcyt-20210729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T00:54:13.041721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}